FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Martin Cheever

Research Profile

Chemicals & Drugs

Living Beings

Anatomy

Physiology

Disorders

Experimental Leukemias

Procedures

Genes & Molecular Sequences

Amino Acid Sequences

Co-author Network

Publications

TOP 3
Martin A Cheever
Twelve immunotherapy drugs that could cure cancers.
S P Mossman; L S Evans; H Fang; J Staas; T Tice; S Raychaudhuri; Kenneth H Grabstein; Martin A Cheever; M E Johnson
Development of a CTL vaccine for Her-2/neu using peptide-microspheres and adjuvants.
Mary L Disis; Kathy Schiffman; Katherine A Guthrie; Lupe G Salazar; Keith L Knutson; Vivian Goodell; Corazon dela Rosa; Martin A Cheever
Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Martin Cheever (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2008: Martin A Cheever
Twelve immunotherapy drugs that could cure cancers.
Immunological reviews 2008;222():357-68.
2005: S P Mossman; L S Evans; H Fang; J Staas; T Tice; S Raychaudhuri; Kenneth H Grabstein; Martin A Cheever; M E Johnson
Development of a CTL vaccine for Her-2/neu using peptide-microspheres and adjuvants.
Vaccine 2005;23(27):3545-54.
2004: Mary L Disis; Kathy Schiffman; Katherine A Guthrie; Lupe G Salazar; Keith L Knutson; Vivian Goodell; Corazon dela Rosa; Martin A Cheever
Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(10):1916-25.
2003: C Rosenfeld; Martin A Cheever; Alexander Gaiger
WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies.
Leukemia 2003;17(7):1301-12.
2003: Michael A Morse; Timothy M Clay; Kirsten Colling; Amy C Hobeika; Kenneth H Grabstein; Martin A Cheever; H Kim Lyerly
HER2 dendritic cell vaccines.
Clinical breast cancer 2003;3 Suppl 4():S164-72.
2002: James L Murray; Michael E Gillogly; Donna Przepiorka; Hannah Brewer; Nuhad K Ibrahim; Daniel J Booser; Gabriel N Hortobagyi; Andrzej P Kudelka; Kenneth H Grabstein; Martin A Cheever; Constantin G Ioannides
Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(11):3407-18.
2002: Craig H Day; Gary R Fanger; Marc W Retter; Bonnie L Hylander; Remedios B Penetrante; Raymond L Houghton; Xinqun Zhang; Patricia D McNeill; Aristides Maltez Filho; Marcos Nolasco; Roberto Badaro; Martin A Cheever; Steven G Reed; Davin C Dillon; Yoshihiro Watanabe
Characterization of KLK4 expression and detection of KLK4-specific antibody in prostate cancer patient sera.
Oncogene 2002;21(46):7114-20.
2002: Teresa M Foy; Gary R Fanger; Susan Hand; Catherine Gerard; Claudine Bruck; Martin A Cheever
Designing HER2 vaccines.
Seminars in oncology 2002;29(3 Suppl 11):53-61.
2002: Mary L Disis; Theodore A Gooley; Kristine Rinn; Donna Davis; Michael Piepkorn; Martin A Cheever; Keith L Knutson; Kathy Schiffman
Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(11):2624-32.
2002: Keith L Knutson; Kathy Schiffman; Martin A Cheever; Mary L Disis
Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(5):1014-8.
2001: Teresa M Foy; J Bannink; R A Sutherland; Patricia D McNeill; G G Moulton; J Smith; Martin A Cheever; Kenneth H Grabstein
Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor.
Vaccine 2001;19(17-19):2598-606.
2001: Alexander Gaiger; L Carter; Hildegard Greinix; Darrick Carter; Patricia D McNeill; Raymond L Houghton; Charisa D Cornellison; Thomas S Vedvick; Yasir A W Skeiky; Martin A Cheever
WT1-specific serum antibodies in patients with leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(3 Suppl):761s-765s.
2000: Alexander Gaiger; V Reese; Mary L Disis; Martin A Cheever
Immunity to WT1 in the animal model and in patients with acute myeloid leukemia.
Blood 2000;96(4):1480-9.
2000: H Bernhard; Eric S Huseby; Susan Hand; M Lohmann; WY Batten; Mary L Disis; Julie R Gralow; KH Meyer zum Büschenfelde; Claes Ohlén; Martin A Cheever
Dendritic cells lose ability to present protein antigen after stimulating antigen-specific T cell responses, despite upregulation of MHC class II expression.
Immunobiology 2000;201(5):568-82.
1999: Mary L Disis; Kenneth H Grabstein; Paul R Sleath; Martin A Cheever
Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(6):1289-97.
1998: Joan G Clark; David K Madtes; Robert C Hackman; W Chen; Martin A Cheever; Paul J Martin
Lung injury induced by alloreactive Th1 cells is characterized by host-derived mononuclear cell inflammation and activation of alveolar macrophages.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(4):1913-20.
1998: W Chen; GS Chatta; W D Rubin; Joan G Clark; Robert C Hackman; David K Madtes; D H Ligitt; Y Kusunoki; Paul J Martin; Martin A Cheever
T cells specific for a polymorphic segment of CD45 induce graft-versus-host disease with predominant pulmonary vasculitis.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(2):909-18.
1998: W Chen; H Qin; V A Reese; Martin A Cheever
CTLs specific for bcr-abl joining region segment peptides fail to lyse leukemia cells expressing p210 bcr-abl protein.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1998;21(4):257-68.
1998: Mary L Disis; F M Shiota; Martin A Cheever
Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for 'self' tumour antigens.
Immunology 1998;93(2):192-9.
1998: Mary L Disis; Martin A Cheever
HER-2/neu oncogenic protein: issues in vaccine development.
Critical reviews in immunology 1998;18(1-2):37-45.
1997: Mary L Disis; Serenella M Pupa; Julie R Gralow; R Dittadi; S Menard; Martin A Cheever
High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(11):3363-7.
1997: J I Clark; R Katherine Alpaugh; Margaret von Mehren; J Schultz; Julie R Gralow; Martin A Cheever; D B Ring; Louis M Weiner
Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment.
Cancer immunology, immunotherapy : CII 1997;44(5):265-72.
1997: K J Liu; GS Chatta; D R Twardzik; Thomas S Vedvick; Lawrence True; A G Spies; Martin A Cheever
Identification of rat prostatic steroid-binding protein as a target antigen of experimental autoimmune prostatitis: implications for prostate cancer therapy.
Journal of immunology (Baltimore, Md. : 1950) 1997;159(1):472-80.
1997: Martin A Cheever; W Chen
Therapy with cultured T cells: principles revisited.
Immunological reviews 1997;157():177-94.
1997: J Lustgarten; Matthias Theobald; C Labadie; D LaFace; P Peterson; Mary L Disis; Martin A Cheever; Linda A Sherman
Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8.
Human immunology 1997;52(2):109-18.
1997: Susan Hand; H Bernhard; Eric S Huseby; W D Rubin; Mary L Disis; Martin A Cheever
In vitro priming to tumor-associated proteins.
Advances in experimental medicine and biology 1997;417():503-9.
1997: Mary L Disis; Martin A Cheever
HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer.
Advances in cancer research 1997;71():343-71.
1996: W Chen; H Qin; B Chesebro; Martin A Cheever
Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors.
Journal of virology 1996;70(11):7773-82.
1996: Mary L Disis; Martin A Cheever
Oncogenic proteins as tumor antigens.
Current opinion in immunology 1996;8(5):637-42.
1996: Mary L Disis; H Bernhard; F M Shiota; S L Hand; Julie R Gralow; Eric S Huseby; S Gillis; Martin A Cheever
Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines.
Blood 1996;88(1):202-10.
1996: Mary L Disis; Julie R Gralow; H Bernhard; S L Hand; W D Rubin; Martin A Cheever
Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(9):3151-8.
1995: H Qin; W Chen; M Takahashi; Mary L Disis; D R Byrd; L McCahill; K A Bertram; Robert G Fenton; David J Peace; Martin A Cheever
CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients.
Cancer research 1995;55(14):2984-7.
1995: Martin A Cheever; Mary L Disis; H Bernhard; Julie R Gralow; S L Hand; Eric S Huseby; H L Qin; M Takahashi; W Chen
Immunity to oncogenic proteins.
Immunological reviews 1995;145():33-59.
1995: H Bernhard; Mary L Disis; S Heimfeld; S Hand; Julie R Gralow; Martin A Cheever
Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood.
Cancer research 1995;55(5):1099-104.
1994: W Chen; E Schweins; X Chen; Olivera J Finn; Martin A Cheever
Retroviral transduction of protein kinase C-gamma into tumor-specific T cells allows antigen-independent long-term growth in IL-2 with retention of functional specificity in vitro and ability to mediate tumor therapy in vivo.
Journal of immunology (Baltimore, Md. : 1950) 1994;153(8):3630-8.
1994: W Chen; Martin A Cheever
Donor T cells can be induced to grow and survive long term in vivo without previous host immunosuppression.
Journal of immunology (Baltimore, Md. : 1950) 1994;152(10):4767-74.
1994: W Chen; V A Reese; Martin A Cheever
T-cells for tumor therapy can be obtained from antigen-loaded sponge implants.
Cancer research 1994;54(4):1065-70.
1994: Mary L Disis; J W Smith; A E Murphy; W Chen; Martin A Cheever
In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein.
Cancer research 1994;54(4):1071-6.
1994: David J Peace; J W Smith; W Chen; S G You; W L Cosand; J Blake; Martin A Cheever
Lysis of ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated ras peptide.
The Journal of experimental medicine 1994;179(2):473-9.
1994: Mary L Disis; H Bernhard; Julie R Gralow; S L Hand; S R Emery; E Calenoff; Martin A Cheever
Immunity to the HER-2/neu oncogenic protein.
Ciba Foundation symposium 1994;187():198-207; discussion 207-11.
1993: Martin A Cheever; W Chen; Mary L Disis; M Takahashi; David J Peace
T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl.
Annals of the New York Academy of Sciences 1993;690():101-12.
1993: David J Peace; J W Smith; Mary L Disis; W Chen; Martin A Cheever
Induction of T cells specific for the mutated segment of oncogenic P21ras protein by immunization in vivo with the oncogenic protein.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;14(2):110-4.
1992: W Chen; David J Peace; D K Rovira; S G You; Martin A Cheever
T-cell immunity to the joining region of p210BCR-ABL protein.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(4):1468-72.
1991: K D Crossland; V K Lee; W Chen; Stanley R Riddell; Philip D Greenberg; Martin A Cheever
T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo.
Journal of immunology (Baltimore, Md. : 1950) 1991;146(12):4414-20.
1991: David J Peace; W Chen; H Nelson; Martin A Cheever
T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes.
Journal of immunology (Baltimore, Md. : 1950) 1991;146(6):2059-65.
1990: D E Kern; J P Klarnet; Martin A Cheever; Philip D Greenberg
Requirements for the generation of a Lyt-2+ T-cell proliferative response to a syngeneic tumor in the absence of L3T4+ T-cells.
Cancer research 1990;50(19):6256-63.
1990: Kirk R Schultz; J P Klarnet; David J Peace; Martin A Cheever; C C Badger; Irwin D Bernstein; Philip D Greenberg
Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells.
Cancer research 1990;50(17):5421-5.
1990: W Chen; V A Reese; Martin A Cheever
Adoptively transferred antigen-specific T cells can be grown and maintained in large numbers in vivo for extended periods of time by intermittent restimulation with specific antigen plus IL-2.
Journal of immunology (Baltimore, Md. : 1950) 1990;144(10):3659-66.
1989: J P Klarnet; D E Kern; Steven K Dower; L A Matis; Martin A Cheever; Philip D Greenberg
Helper-independent CD8+ cytotoxic T lymphocytes express IL-1 receptors and require IL-1 for secretion of IL-2.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(7):2187-91.
1989: Philip D Greenberg; J P Klarnet; D E Kern; K Okuno; Stanley R Riddell; Martin A Cheever
Specific adoptive immunotherapy.
Progress in clinical and biological research 1989;288():349-61.
1989: David J Peace; Martin A Cheever
Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia.
The Journal of experimental medicine 1989;169(1):161-73.
1988: D E Kern; David J Peace; J P Klarnet; Martin A Cheever; Philip D Greenberg
Il-4 is an endogenous T cell growth factor during the immune response to a syngeneic retrovirus-induced tumor.
Journal of immunology (Baltimore, Md. : 1950) 1988;141(8):2824-30.
1988: David J Peace; D E Kern; Kirk R Schultz; Philip D Greenberg; Martin A Cheever
IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes.
Journal of immunology (Baltimore, Md. : 1950) 1988;140(10):3679-85.
1988: Philip D Greenberg; J P Klarnet; D E Kern; Martin A Cheever
Therapy of disseminated tumors by adoptive transfer of specifically immune T cells.
Progress in experimental tumor research 1988;32():104-27.
1988: P Greenberg; J Klarnet; D Kern; K Okuno; Stanley R Riddell; Martin A Cheever
Requirements for T cell recognition and elimination of retrovirally-transformed cells.
Princess Takamatsu symposia 1988;19():287-301.
1987: J P Klarnet; L A Matis; D E Kern; M T Mizuno; David J Peace; JA Thompson; Philip D Greenberg; Martin A Cheever
Antigen-driven T cell clones can proliferate in vivo, eradicate disseminated leukemia, and provide specific immunologic memory.
Journal of immunology (Baltimore, Md. : 1950) 1987;138(11):4012-7.
1987: Martin A Cheever; J P Klarnet; David J Peace; Philip D Greenberg
Antigen-specific cultured T cells can mediate tumor therapy and provide long-term immunologic memory in vivo.
Progress in clinical and biological research 1987;244():49-58.
1987: Philip D Greenberg; D E Kern; M C Jensen; J P Klarnet; Martin A Cheever
Effector mechanisms by which adoptively transferred T cells promote tumor eradication.
Progress in clinical and biological research 1987;244():127-35.
1986: JA Thompson; David J Peace; J P Klarnet; D E Kern; Philip D Greenberg; Martin A Cheever
Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2.
Journal of immunology (Baltimore, Md. : 1950) 1986;137(11):3675-80.
1986: Martin A Cheever; D B Thompson; J P Klarnet; Philip D Greenberg
Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells.
The Journal of experimental medicine 1986;163(5):1100-12.